This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
iot: Archive
ACLS Falls 22.4% in Past Month as Recovery Meets Fresh Margin Pressure
by Supriyo Bose
Axcelis shares fell 22.4% in a month as recovering bookings and demand collide with weaker margins, backlog pressure and heavy China exposure.
ACLSNegative Net Change LRCXNegative Net Change AMATNegative Net Change
electronics iot tech-stocks
Should Investors Buy ACLS as Growth Returns Despite Premium Valuation?
by Supriyo Bose
Axcelis growth is returning as memory, power and aftermarket demand improve, but premium valuation and incomplete margin recovery keep execution in focus.
ACLSNegative Net Change LRCXNegative Net Change AMATNegative Net Change VECOPositive Net Change
artificial-intelligence electronics iot tech-stocks
ACLS Invests $35M in Korea To Expand Its Manufacturing Infrastructure
by Supriyo Bose
Axcelis plans a $35M South Korea ion implantation facility to expand Asian capacity as memory, power and mature-node activity improves.
ACLSNegative Net Change LRCXNegative Net Change AMATNegative Net Change
electronics iot tech-stocks
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
PMVPPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Space Weapons Put SPCX in Market Spotlight: Should You Buy the Stock?
by Supriyo Bose
SPCX's $8.05 billion in announced defense awards, Starshield contracts and Golden Dome role put its expanding military-space business in focus.
LMTPositive Net Change NOCNegative Net Change
artificial-intelligence communications iot mobile tech-stocks
Aviat Plunges 16% in a Year: Should Investors Avoid the Stock Now?
by Supriyo Bose
AVNW faces margin pressure, weaker services and international sales and back-end-loaded 2027 targets as investors await stronger cash flow.
ERICNegative Net Change ASTSPositive Net Change
communications iot tech-stocks
IDCC Gains Just 5% in a Year: Should It Still Be in Your Portfolio?
by Supriyo Bose
InterDigital's record recurring revenues, Amazon licensing deal and raised 2026 outlook bolster its case despite a modest 5.2% one-year share gain.
AMZNNegative Net Change ERICNegative Net Change ASTSPositive Net Change
artificial-intelligence communications iot mobile tech-stocks
Can the Formation of Equatys Help Revive Viasat's Growth Momentum?
by Supriyo Bose
VSAT's Equatys venture could unlock new D2D revenue, broaden its market and improve capital efficiency through shared satellite infrastructure.
VSATPositive Net Change CMTLPositive Net Change ASTSPositive Net Change
artificial-intelligence communications iot tech-stocks
BB Radar Expands Asset Intelligence: New Growth Engine in the Making?
by Zacks Equity Research
BlackBerry is positioning Radar as an Asset Intelligence Platform, with DCLI's 100,000-chassis deployment showcasing its potential beyond GPS tracking.
BBNegative Net Change QCOMNegative Net Change NVDAPositive Net Change
automation autonomous-vehicles computers internet iot robotics saas tech-stocks
KANZHUN LIMITED Sponsored ADR (BZ) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
BZNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines